Novavax, Inc (NASDAQ: NVAX) kicked off on Friday, down -3.58% from the previous trading day, before settling in for the closing price of $7.26. Over the past 52 weeks, NVAX has traded in a range of $3.81-$23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 516.28% over the last five years. While this was happening, its average annual earnings per share was recorded 81.77%. With a float of $146.57 million, this company’s outstanding shares have now reached $160.42 million.
The firm has a total of 952 workers. Let’s measure their productivity. In terms of profitability, gross margin is 73.3%, operating margin of -35.6%, and the pretax margin is -25.89%.
Novavax, Inc (NVAX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc is 8.87%, while institutional ownership is 59.79%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.
Novavax, Inc (NVAX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 81.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 67.92% during the next five years compared to 25.88% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Take a look at Novavax, Inc’s (NVAX) current performance indicators. Last quarter, stock had a quick ratio of 0.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach 0.55 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Analysing the last 5-days average volume posted by the [Novavax, Inc, NVAX], we can find that recorded value of 2.58 million was lower than the volume posted last year of 4.29 million. As of the previous 9 days, the stock’s Stochastic %D was 5.83%. Additionally, its Average True Range was 0.43.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 4.01%, which indicates a significant decrease from 4.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.36% in the past 14 days, which was lower than the 68.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.14, while its 200-day Moving Average is $10.59. Now, the first resistance to watch is $7.22. This is followed by the second major resistance level at $7.43. The third major resistance level sits at $7.58. If the price goes on to break the first support level at $6.86, it is likely to go to the next support level at $6.71. Now, if the price goes above the second support level, the third support stands at $6.50.
Novavax, Inc (NASDAQ: NVAX) Key Stats
The company with the Market Capitalisation of 1.13 billion has total of 160,844K Shares Outstanding. Its annual sales at the moment are 682,160 K in contrast with the sum of -187,500 K annual income. Company’s last quarter sales were recorded 88,310 K and last quarter income was -81,030 K.
